Journal
ANTICANCER RESEARCH
Volume 43, Issue 3, Pages 1043-1052Publisher
INT INST ANTICANCER RESEARCH
DOI: 10.21873/anticanres.16249
Keywords
ADAM9; MICA; NKG2D; HCC; CCL347
Categories
Ask authors/readers for more resources
In this study, the inhibition of ADAM9 was found to prevent the release of MICA and activate the immune function of NK cells. Through the screening of a chemical library, a compound called CCL347 with five benzene rings was identified, which significantly reduced sMICA levels in HCC cell lines and enhanced NK cell cytotoxicity, indicating its potential as a novel therapeutic drug for HCC.
Background/Aim: MHC-class I-related chain A (MICA) functions as a ligand for natural killer group D, an activating receptor on natural killer (NK) cells, and its expression correlates with the carcinogenesis and progression of hepatocellular carcinoma (HCC). Although membranous MICA (mMICA) activates NK cells, soluble forms of MICA (sMICA), shed by cleaving enzymes, such as A disintegrin and metalloprotease (ADAM) 9, suppress NK cells. Therefore, the prevention of MICA shedding through the inhibition of ADAM9 has the potential to activate cancer immunity. Although we have discovered several ADAM inhibitors, many did not sufficiently activate NK cells without being cytotoxic, and, thus, new ADAM9 inhibitor candidates are needed. Materials and Methods: To identify possible compounds for drug development, chemical library screening (a total of 741 compounds) was conducted using a fluorescence assay. Compounds with reduced fluorescence intensity were used as hit compounds in a subsequent analysis. Their impact on sMICA and mMICA in HCC cell lines was assessed using ELISA and flow cytometry, respectively. The cytotoxicity of NK cells was also evaluated by co-culturing NK cells with HCC cells. Results: CCL347, a symmetrical compound with five benzene rings, was identified as a hit compound. CCL347 significantly reduced sMICA levels in the culture medium supernatant with negligible cytotoxicity. Although mMICA was also reduced, CCL347 successfully enhanced NK cell cytotoxicity in co -cultures of NK cells and HCC cells.Conclusion: CCL347 has potential as a novel therapeutic drug for HCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available